https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=IONIS_PHARMACEUTICALS_INCIONIS PHARMACEUTICALS INC - Revizia istoricului2026-04-04T15:11:32ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=IONIS_PHARMACEUTICALS_INC&diff=425987&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei IONIS PHARMACEUTICALS INC listata cu simbolul US.ISIS ==Descriere companie== Ionis Pharmaceuticals, Inc. (https://www.ionispharma.com/) is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a p...2024-09-18T18:05:44Z<p>Pagină nouă: Pagina dedicata companiei IONIS PHARMACEUTICALS INC listata cu simbolul US.ISIS ==Descriere companie== Ionis Pharmaceuticals, Inc. (https://www.ionispharma.com/) is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a p...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei IONIS PHARMACEUTICALS INC listata cu simbolul US.ISIS<br />
<br />
==Descriere companie==<br />
Ionis Pharmaceuticals, Inc. (https://www.ionispharma.com/) is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ISIS" /><br />
<br />
==Ultimele stiri despre IONIS PHARMACEUTICALS INC (US.ISIS)==<br />
<dynamicpagelist><br />
category=US.ISIS<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ISIS]][[Categorie:Stiri despre companii]]</div>Admin